Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 31, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after
View HTML
Toggle Summary Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the
View HTML
Toggle Summary Xencor Appoints Nancy Valente, M.D., to Board of Directors
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to its board of
View HTML
Toggle Summary Xencor Reports Second Quarter 2022 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 3, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
View HTML
Toggle Summary Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ --  Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage
View HTML
Toggle Summary Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after
View HTML
Toggle Summary Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
MONROVIA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating
View HTML
Toggle Summary Xencor Reports First Quarter 2022 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
View HTML
Toggle Summary Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results
View HTML
Toggle Summary Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage
View HTML